达雷妥尤单抗通过靶向CD38阳性自然杀伤细胞诱导免疫激活机制
达雷妥尤单抗(Dara)虽降低总NK细胞频率,但NK细胞在其抗骨髓瘤活性中起关键作用。Dara靶向CD38阳性NK细胞诱导CD38快速降解并激活NK细胞,促进单核细胞活化与T细胞共刺激分子CD86/80增加,增强体内外抗骨髓瘤吞噬活性。因疾病进展停药的患者骨髓瘤细胞仍保留可靶向的未突变表面CD38,但效应细胞免疫功能受损。
要点
- Dara虽降低总NK细胞频率,但NK细胞在Dara抗骨髓瘤活性中起关键作用
- Dara靶向CD38阳性NK细胞诱导CD38快速降解,留下活化的CD38阴性NK细胞群
- Dara靶向CD38阳性NK细胞促进单核细胞活化,增加CD86/80并增强抗骨髓瘤吞噬
核心结论
- CD38阳性NK细胞可能是启动骨髓瘤患者免疫系统的未探索治疗靶点。
研究设计与样本
- 原文未报告研究设计与样本量。
主要发现
- Dara虽降低总NK细胞频率,但NK细胞在Dara抗骨髓瘤活性中起关键作用。
- NK细胞上的CD38对Dara诱导的免疫调节至关重要,其表达局限于具有效应功能的NK细胞。
- Dara诱导与NK细胞活化相关的CD38快速蛋白降解,留下活化的CD38阴性NK细胞群。
- Dara靶向CD38阳性NK细胞促进单核细胞活化,诱导T细胞共刺激分子CD86/80增加,并增强体内外抗骨髓瘤吞噬活性。
- 因进展停用Dara的骨髓瘤患者,其骨髓瘤细胞仍维持可靶向的未突变表面CD38表达,但效应细胞免疫功能受损。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Daratumumab (Dara), a multiple myeloma (MM) therapy, is an antibody against the surface receptor CD38, which is expressed not only on plasma cells but also on NK cells and monocytes. Correlative data have highlighted the immune-modulatory role of Dara, despite the paradoxical observation that Dara regimens decrease the frequency of total NK cells. Here we show that, despite this reduction, NK cells play a pivotal role in Dara anti-MM activity. CD38 on NK cells is essential for Dara-induced immune modulation, and its expression is restricted to NK cells with effector function. We also show that Dara induces rapid CD38 protein degradation associated with NK cell activation, leaving an activated CD38-negative NK cell population. CD38+ NK cell targeting by Dara also promotes monocyte activation, inducing an increase in T-cell costimulatory molecules (CD86/80) and enhancing anti-MM phagocytosis activity ex vivo and in vivo. In support of Dara's immunomodulating role, we show that MM patients that discontinued Dara therapy because of progression maintain targetable unmutated surface CD38 expression on their MM cells, but retain effector cells with impaired cellular immune function. In summary, we report that CD38+ NK cells may be an unexplored therapeutic target for priming the immune system of MM patients.
引用
- Viola D, Dona A, Caserta E, et al. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia. 2020. PMID: 32296125. doi:10.1038/s41375-020-0810-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。